Restricted accessLetterFirst published online 2021-12
Importance of Disease Recognition and Proper Disease Nomenclature for Patients With Acid Sphingomyelinase Deficiency (Historically Known as Niemann-Pick Types A or B) With a Disease-Specific Treatment on the Horizon
BaldwinKPGonzalez-GomezIWilseyMKarjooS. An unusual presentation of failure to thrive. Clin Pediatr (Phila). 2020;59:201-204.
2.
SunA. Lysosomal storage disease overview. Ann Transl Med. 2018;6:476.
3.
McGovernMMLippaNBagiellaESchuchmanEHDesnickRJWassersteinMP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med. 2013;15:618-623.
4.
McGovernMMDionisis-ViciCGiuglianiR, et al. Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency. Genet Med. 2017;19:967-974.
5.
WassersteinMPDiazGALachmannRH, et al. Olipudase alfa for the treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. J Inherit Metab Dis. 2018;41:829-838.
6.
DiazGAJonesSAScarpaM, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet Med. 2021;23:1543-1550.
7.
WassersteinMPArash-KapsLBarbatoA, et al. OP093—One-year results of the placebo-controlled ASCEND trial of olipudase alfa enzyme replacement therapy in adults with chronic acid sphingomyelinase deficiency. Mol Genet Metabol. 2021;132:S64-S65.
